Harvard Bioscience Inc revenue
Harvard Bioscience Inc's revenue was $86.5m in fiscal 2025, down 8.1% on the year before. Since fiscal 2009 ($85.8m) it has grown at a compound 0.1% a year. Over the last twelve months it was $87.8m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86 | 108 | 109 | 111 | 105 | 109 | 109 | 105 | 77 | 121 | 116 | 102 | 119 | 113 | 112 | 94 | 87 | 88 |
| Growth on the year before | — | +26.1% | +0.6% | +2.1% | −5.4% | +3.3% | +0.0% | −3.8% | −25.9% | +56.0% | −3.8% | −12.1% | +16.5% | −4.7% | −1.0% | −16.1% | −8.1% | — |
| Gross profit | 42 | 52 | 50 | 52 | 48 | 49 | 49 | 48 | 39 | 63 | 64 | 58 | 68 | 61 | 66 | 55 | 50 | 51 |
| Gross margin | 48.6% | 47.9% | 46.1% | 47.1% | 45.4% | 45.4% | 44.8% | 46.3% | 50.6% | 52.3% | 55.4% | 56.8% | 56.9% | 53.7% | 58.9% | 58.2% | 57.7% | 58.2% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Instruments Equipment Software and Accessories | $78.3M | 90.4% | ▼ 10.0% |
| Service Maintenance and Warranty Contracts | $8.3M | 9.6% | ▲ 15.6% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $39M | 45.0% | ▼ 6.6% |
| EMEA | $26.7M | 30.9% | ▼ 6.0% |
| China | $11M | 12.7% | ▼ 17.5% |
| Asia Other | $6.7M | 7.7% | ▼ 5.9% |
| Americas Other | $3.2M | 3.7% | ▼ 10.3% |
From Harvard Bioscience Inc's 10-K filed March 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Harvard Bioscience Inc | $87.8m | -1.1% | -8.4% |
| Codexis, Inc. | $77.7m | 35.9% | -7.8% |
| Burning Rock Biotech Ltd | $75.1m | 4.7% | — |
| Biodesix Inc | $103m | 34.5% | 35.2% |
| Mdxhealth SA | $108m | 19.8% | — |
| Exagen Inc. | $71.1m | 20.8% | 10.3% |
Compare with peers
- Codexis, Inc. revenue
- Burning Rock Biotech Ltd revenue
- Biodesix Inc revenue
- Mdxhealth SA revenue
- Exagen Inc. revenue
Head to head: CDXS vs HBIOBNR vs HBIOBDSX vs HBIOHBIO vs MDXH
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies